Cortical somatosensory evoked potential amplitudes and clinical outcome after cardiac arrest: a retrospective multicenter study.

"blinded for clinical data digitalized sseps were analyzed using custom-written matlab scripts (release 2019b mathworks inc) following a standardized evaluation pathway [ ] (supplementary fig 1 and supplementary fig 2)."

"Declarations Conflicts of interestKH received financial reimbursement for consulting, advisory board activities, speaker fees and contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. KH declared that none of this is related to the manuscript. JN reported receiving personal fees for consultancy and speaker fees from BD Bard. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Ethical approvalLocal ethics committees fully approved this study and waived the need for patient consent (EA4/004/14). The study was conducted according to the Declaration of Helsinki. Conflicts of interest KH received financial reimbursement for consulting, advisory board activities, speaker fees and contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc. and Swedish Orphan Biovitrum Inc. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. KH declared that none of this is related to the manuscript. JN reported receiving personal fees for consultancy and speaker fees from BD Bard. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL. KH is a participant in the BIH Clinical Fellow Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH), and received a research grant from Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. MK is a participant in the BIH Charité Junior Digital Clinician Scientist Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH). MK also received a grant from the Laerdal Foundation (grant number 2021-0040). CL is a participant in the BIH Clinical Fellow Program funded by the Charité—Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH). CE was granted with research fellowship by the Laerdal Foundation (grant number 2021-67) to conduct this study. The research grants had no role in study concept, data collection and analysis, decision to publish, or preparation of the manuscript."